ACADIA Pharmaceuticals Valuation
| ACAD Stock | USD 18.69 0.32 1.74% |
At this time, the entity appears to be undervalued. ACADIA Pharmaceuticals owns a latest Real Value of $21.36 per share. The recent price of the entity is $18.69. Our model approximates the value of ACADIA Pharmaceuticals from examining the entity fundamentals such as shares outstanding of 166.39 M, and Return On Asset of 0.0872 as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ACADIA Pharmaceuticals' valuation include:
Price Book 5.2958 | Enterprise Value | Enterprise Value Ebitda 20.4002 | Price Sales 3.3467 | Forward PE 25.5102 |
Undervalued
Today
Please note that ACADIA Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of ACADIA Pharmaceuticals is based on 3 months time horizon. Increasing ACADIA Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ACADIA stock is determined by what a typical buyer is willing to pay for full or partial control of ACADIA Pharmaceuticals. Since ACADIA Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ACADIA Stock. However, ACADIA Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.69 | Real 21.36 | Target 24.95 | Hype 18.74 | Naive 19.59 |
The real value of ACADIA Stock, also known as its intrinsic value, is the underlying worth of ACADIA Pharmaceuticals Company, which is reflected in its stock price. It is based on ACADIA Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ACADIA Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ACADIA Pharmaceuticals helps investors to forecast how ACADIA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ACADIA Pharmaceuticals more accurately as focusing exclusively on ACADIA Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ACADIA Pharmaceuticals' intrinsic value based on its ongoing forecasts of ACADIA Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ACADIA Pharmaceuticals' closest peers. If more than one evaluation category is relevant for ACADIA Pharmaceuticals we suggest using both methods to arrive at a better estimate.
ACADIA Pharmaceuticals Cash |
|
ACADIA Valuation Trend
Comparing ACADIA Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of ACADIA Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
ACADIA Pharmaceuticals Total Value Analysis
ACADIA Pharmaceuticals is presently forecasted to have valuation of 2.54 B with market capitalization of 3.11 B, debt of 57.2 M, and cash on hands of 436.35 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ACADIA Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.54 B | 3.11 B | 57.2 M | 436.35 M |
ACADIA Pharmaceuticals Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the 30th of June 2010. Based on the key indicators related to ACADIA Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ACADIA Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.ACADIA Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ACADIA Pharmaceuticals has an asset utilization ratio of 96.99 percent. This indicates that the Company is making $0.97 for each dollar of assets. An increasing asset utilization means that ACADIA Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.ACADIA Pharmaceuticals Ownership Allocation
ACADIA Pharmaceuticals secures a total of 166.39 Million outstanding shares. The majority of ACADIA Pharmaceuticals outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in ACADIA Pharmaceuticals to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in ACADIA Pharmaceuticals. Please pay attention to any change in the institutional holdings of ACADIA Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.ACADIA Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 726.44 M. Net Loss for the year was (61.29 M) with profit before overhead, payroll, taxes, and interest of 582.05 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ACADIA Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ACADIA Pharmaceuticals and how it compares across the competition.
About ACADIA Pharmaceuticals Valuation
The stock valuation mechanism determines ACADIA Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of ACADIA Pharmaceuticals. We calculate exposure to ACADIA Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ACADIA Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 782.8 M | 822 M | |
| Pretax Profit Margin | (0.08) | (0.08) | |
| Operating Profit Margin | (0.10) | (0.12) | |
| Net Loss | (0.10) | (0.10) | |
| Gross Profit Margin | 0.84 | 0.89 |
ACADIA Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as ACADIA Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 163.8 M | |
| Quarterly Earnings Growth Y O Y | 28.347 | |
| Forward Price Earnings | 25.5102 |
ACADIA Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of ACADIA Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ACADIA we look at many different elements of the entity such as ACADIA's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ACADIA Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ACADIA Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ACADIA Pharmaceuticals' worth.Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |